Q4 Results Highlights – May 13, 2026
On May 13, 2026, several companies announced their Q4 earnings, highlighting key financial developments across various sectors. Notable results include:
-
Metropolis Healthcare: The company’s consolidated profit after tax (PAT) rose 74% to ₹50.96 crore. Q4 revenue from operations increased to ₹424.68 crore from ₹345.29 crore, with total expenses rising to ₹363.19 crore. The board approved a second dividend of Re 1 per share for FY26.
-
Crompton Greaves Consumer Electricals: The company reported a consolidated net loss of ₹531.07 crore in Q4, attributed to a ₹716.04 crore impairment on its Butterfly subsidiary investment and trademarks. However, revenue from operations grew to ₹2,283.27 crore, up from ₹2,060.82 crore, while total expenses reached ₹2,066.63 crore. For FY26, the consolidated net loss totaled ₹230.76 crore.
-
Shriram General Insurance: Net profit climbed 28% to ₹167 crore for Q4, contributing to a 17% increase to ₹601 crore for FY26. Gross direct premium income in Q4 grew 21% to ₹1,332 crore, reflecting robust growth in the motor insurance portfolio.
-
GK Energy: Consolidated net profit reached ₹59.2 crore, up 32%. Total income increased to ₹479.2 crore, driven by strong performance in renewable energy infrastructure.
-
DLF: The developer reported a slight decline of 1% in consolidated net profit to ₹1,268.56 crore for Q4, with total income falling to ₹2,093.82 crore from ₹3,347.77 crore. However, FY26 net profit rose to ₹4,414.68 crore.
-
Oil India: The company experienced a 62% increase in net profit to ₹2,424 crore in Q4, alongside a 6% boost in crude oil production. It also noted an increase in crude price realization to $77.89 per barrel and recommended a final dividend of ₹1 per share.
-
Airtel: The telecom operator’s Q4 net profit fell 33% year-on-year to ₹7,325 crore despite a 16% revenue growth. The mobile average revenue per user (ARPU) was recorded at ₹257.
-
ABOTT India: Abbott declared a substantial ₹656 dividend per share—among the highest in the Indian pharma sector. Q4 revenue rose 6.5% year-on-year to ₹1,709 crore, with EBITDA increasing by 12.2% to ₹481 crore.
These financial announcements illustrate a mixed but generally positive trend among companies, with several reporting significant profit and revenue growth despite economic pressures.
